AIP
PRAX icon

Arrowpoint Investment Partners’s Praxis Precision Medicines PRAX Stock Holding History

Arrowpoint Investment Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Buy
3,855
+1,773
+85% +$548K 1.1% 21
2025
Q4 		$614K Buy
+2,082
New +$388K 0.09% 63

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Arrowpoint Investment Partners's PRAX Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its Praxis Precision Medicines (PRAX) stake by 85% in Q1 2026, buying an estimated $548K and bringing the position to 3,855 shares worth $1.24M. The position accounts for 1.1% of the portfolio, ranked #21.

Arrowpoint Investment Partners first reported a position in PRAX in Q4 2025 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Arrowpoint Investment Partners held 3,855 shares of Praxis Precision Medicines worth $1.24M as of Q1 2026.
  • Arrowpoint Investment Partners bought 1,773 Praxis Precision Medicines shares in Q1 2026, an estimated $548K.
  • Praxis Precision Medicines made up 1.1% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #21 holding.
  • Arrowpoint Investment Partners first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.